204 related articles for article (PubMed ID: 34326139)
1. Infigratinib Is a Reversible Inhibitor and Mechanism-Based Inactivator of Cytochrome P450 3A4.
Tang LWT; Teng JW; Verma RK; Koh SK; Zhou L; Go ML; Fan H; Chan ECY
Drug Metab Dispos; 2021 Sep; 49(9):856-868. PubMed ID: 34326139
[TBL] [Abstract][Full Text] [Related]
2. Mechanism-Based Inactivation of Cytochrome P450 3A4 by Benzbromarone.
Tang LWT; Verma RK; Fan H; Chan ECY
Mol Pharmacol; 2021 Apr; 99(4):266-276. PubMed ID: 33436520
[TBL] [Abstract][Full Text] [Related]
3. Identification of Infigratinib as a Potent Reversible Inhibitor and Mechanism-Based Inactivator of CYP2J2: Nascent Evidence for a Potential In Vivo Metabolic Drug-Drug Interaction with Rivaroxaban.
Tang LWT; Wu G; Chan ECY
J Pharmacol Exp Ther; 2022 Aug; 382(2):123-134. PubMed ID: 35640957
[TBL] [Abstract][Full Text] [Related]
4. Direct and Sequential Bioactivation of Pemigatinib to Reactive Iminium Ion Intermediates Culminates in Mechanism-Based Inactivation of Cytochrome P450 3A.
Tang LWT; Wei W; Verma RK; Koh SK; Zhou L; Fan H; Chan ECY
Drug Metab Dispos; 2022 May; 50(5):529-540. PubMed ID: 35153194
[TBL] [Abstract][Full Text] [Related]
5. Mechanism-Based Inactivation of Cytochrome P450 3A4 and 3A5 by the Fibroblast Growth Factor Receptor Inhibitor Erdafitinib.
Tang LWT; Teng JW; Koh SK; Zhou L; Go ML; Chan ECY
Chem Res Toxicol; 2021 Jul; 34(7):1800-1813. PubMed ID: 34189909
[TBL] [Abstract][Full Text] [Related]
6. Metabolic Activation of the Acrylamide Michael Acceptor Warhead in Futibatinib to an Epoxide Intermediate Engenders Covalent Inactivation of CYP3A.
Tang LWT; Fu J; Koh SK; Wu G; Zhou L; Chan ECY
Drug Metab Dispos; 2022 Jul; 50(7):931-941. PubMed ID: 35512804
[TBL] [Abstract][Full Text] [Related]
7. Inactivation of Human Cytochrome P450 3A4 and 3A5 by Dronedarone and N-Desbutyl Dronedarone.
Hong Y; Chia YM; Yeo RH; Venkatesan G; Koh SK; Chai CL; Zhou L; Kojodjojo P; Chan EC
Mol Pharmacol; 2016 Jan; 89(1):1-13. PubMed ID: 26490246
[TBL] [Abstract][Full Text] [Related]
8. NADPH-Independent Inactivation of CYP2B6 and NADPH-Dependent Inactivation of CYP3A4/5 by PBD: Potential Implication for Assessing Covalent Modulators for Time-Dependent Inhibition.
Kosaka M; Zhang D; Wong S; Yan Z
Drug Metab Dispos; 2020 Aug; 48(8):655-661. PubMed ID: 32482757
[TBL] [Abstract][Full Text] [Related]
9. Icotinib Induces Mechanism-Based Inactivation of Recombinant Human CYP3A4/5 Possibly via Heme Destruction by Ketene Intermediate.
Sun C; Zhao H; Li W; Jia Y; Yang Y; Peng Y; Zheng J
Drug Metab Dispos; 2021 Oct; 49(10):892-901. PubMed ID: 34312304
[TBL] [Abstract][Full Text] [Related]
10. Mechanism-based inactivation of cytochrome P-450-3A4 by mifepristone (RU486).
He K; Woolf TF; Hollenberg PF
J Pharmacol Exp Ther; 1999 Feb; 288(2):791-7. PubMed ID: 9918590
[TBL] [Abstract][Full Text] [Related]
11. Differential Reversible and Irreversible Interactions between Benzbromarone and Human Cytochrome P450s 3A4 and 3A5.
Tang LWT; Verma RK; Yong RP; Li X; Wang L; Lin Q; Fan H; Chan ECY
Mol Pharmacol; 2021 Sep; 100(3):224-236. PubMed ID: 34210765
[TBL] [Abstract][Full Text] [Related]
12. Tofacitinib Is a Mechanism-Based Inactivator of Cytochrome P450 3A4.
Guo X; Li W; Li Q; Chen Y; Zhao G; Peng Y; Zheng J
Chem Res Toxicol; 2019 Sep; 32(9):1791-1800. PubMed ID: 31414593
[TBL] [Abstract][Full Text] [Related]
13. Mechanism-based inactivation of cytochrome P450 3A4 by 17 alpha-ethynylestradiol: evidence for heme destruction and covalent binding to protein.
Lin HL; Kent UM; Hollenberg PF
J Pharmacol Exp Ther; 2002 Apr; 301(1):160-7. PubMed ID: 11907170
[TBL] [Abstract][Full Text] [Related]
14. Metabolic intermediate complex formation of human cytochrome P450 3A4 by lapatinib.
Takakusa H; Wahlin MD; Zhao C; Hanson KL; New LS; Chan EC; Nelson SD
Drug Metab Dispos; 2011 Jun; 39(6):1022-30. PubMed ID: 21363997
[TBL] [Abstract][Full Text] [Related]
15. Piperine Is a Mechanism-Based Inactivator of CYP3A.
Cui T; Wang Q; Tian X; Zhang K; Peng Y; Zheng J
Drug Metab Dispos; 2020 Feb; 48(2):123-134. PubMed ID: 31748224
[TBL] [Abstract][Full Text] [Related]
16. Mechanism-based inactivation of cytochrome P450 3A4 by lapatinib.
Teng WC; Oh JW; New LS; Wahlin MD; Nelson SD; Ho HK; Chan EC
Mol Pharmacol; 2010 Oct; 78(4):693-703. PubMed ID: 20624855
[TBL] [Abstract][Full Text] [Related]
17. Bioactivation of a novel 2-methylindole-containing dual chemoattractant receptor-homologous molecule expressed on T-helper type-2 cells/D-prostanoid receptor antagonist leads to mechanism-based CYP3A inactivation: glutathione adduct characterization and prediction of in vivo drug-drug interaction.
Wong SG; Fan PW; Subramanian R; Tonn GR; Henne KR; Johnson MG; Tadano Lohr M; Wong BK
Drug Metab Dispos; 2010 May; 38(5):841-50. PubMed ID: 20100816
[TBL] [Abstract][Full Text] [Related]
18. Imidazoacridinone antitumor agent C-1311 as a selective mechanism-based inactivator of human cytochrome P450 1A2 and 3A4 isoenzymes.
Potęga A; Fedejko-Kap B; Mazerska Z
Pharmacol Rep; 2016 Aug; 68(4):663-70. PubMed ID: 27110874
[TBL] [Abstract][Full Text] [Related]
19. Characterization of ritonavir-mediated inactivation of cytochrome P450 3A4.
Rock BM; Hengel SM; Rock DA; Wienkers LC; Kunze KL
Mol Pharmacol; 2014 Dec; 86(6):665-74. PubMed ID: 25274602
[TBL] [Abstract][Full Text] [Related]
20. Mechanism-based inactivation of human cytochrome P450 3A4 by two piperazine-containing compounds.
Bolles AK; Fujiwara R; Briggs ED; Nomeir AA; Furge LL
Drug Metab Dispos; 2014 Dec; 42(12):2087-96. PubMed ID: 25273356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
